Trial intelligence / Profile preview

Disitamab Vedotin, Sintilimab, and Radiotherapy in HER2+ Advanced Gastric Cancer

NCT07490990Phase 2Not yet recruiting

Sponsor: West China Hospital of Sichuan University
Start: Jun 2026
Primary completion: Jun 2028

Overview

A Phase 2 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Planned start Jun 2026; status: not yet recruiting.

Drugs

disitamab vedotin

Conditions

gastric cancer (GC)gastroesophageal junction adenocarcinoma

Beyond the preview

Go deeper on NCT07490990.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07490990.